Literature DB >> 23748238

PET/CT and breast cancer subtypes.

Laura Gilardi1, Marco Colleoni, Giovanni Paganelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23748238     DOI： 10.1007/s00259-013-2472-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  30 in total

Review 1.  Practical implications of gene-expression-based assays for breast oncologists.

Authors:  Aleix Prat; Matthew J Ellis; Charles M Perou
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

2.  Molecular stratification of triple-negative breast cancers.

Authors:  Charles M Perou
Journal:  Oncologist       Date:  2011

3.  Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers.

Authors:  F-C Bidard; R Conforti; T Boulet; S Michiels; S Delaloge; F André
Journal:  Ann Oncol       Date:  2007-07       Impact factor: 32.976

4.  Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment.

Authors:  Giuseppe Viale
Journal:  Breast       Date:  2009-10       Impact factor: 4.380

5.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.

Authors:  Aleix Prat; Maggie Chon U Cheang; Miguel Martín; Joel S Parker; Eva Carrasco; Rosalía Caballero; Scott Tyldesley; Karen Gelmon; Philip S Bernard; Torsten O Nielsen; Charles M Perou
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

6.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

7.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

8.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

9.  Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes.

Authors:  O Humbert; A Berriolo-Riedinger; J M Riedinger; B Coudert; L Arnould; A Cochet; C Loustalot; P Fumoleau; F Brunotte
Journal:  Ann Oncol       Date:  2012-04-12       Impact factor: 32.976

10.  Increased FDG uptake in breast cancer is associated with prognostic factors.

Authors:  Yasemin Sanli; Serkan Kuyumcu; Zeynep Gozde Ozkan; Göknur Işik; Hasan Karanlik; Burcu Guzelbey; Cuneyt Turkmen; Sevda Ozel; Ekrem Yavuz; Ayse Mudun
Journal:  Ann Nucl Med       Date:  2012-02-24       Impact factor: 2.668
View more
  1 in total

Review 1.  The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer.

Authors:  Koosha Paydary; Siavash Mehdizadeh Seraj; Mahdi Zirakchian Zadeh; Sahra Emamzadehfard; Sara Pourhassan Shamchi; Saeid Gholami; Thomas J Werner; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.